Skip to main content
SYRE
NASDAQ Life Sciences

SPY002 Posts Highly Positive Phase 2 Results for Ulcerative Colitis

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$82.5
Mkt Cap
$7.016B
52W Low
$13.93
52W High
$84.43
52W Position info
492% above low
Off High info
2.3% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SYRE has more than doubled off its 52-week low of $13.93.

Summary

Spyre Therapeutics announced highly positive Phase 2 SKYLINE Part A results for its drug candidate SPY002 in ulcerative colitis. The trial met its primary endpoint, showing a significant 10.7-point reduction in the Robarts Histopathology Index (p<0.0001), alongside high clinical remission (33%) and endoscopic improvement (42%) rates. This news follows an 8-K filing minutes earlier and builds on the company's strong pipeline, which also saw positive Phase 2 data for SPY001 in April. These robust results validate SPY002's potential in a competitive therapeutic area and are critical for a company trading near its 52-week high. Enrollment for Part B combination arms is currently underway.

At the time of this announcement, SYRE was trading at $82.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7B. The 52-week trading range was $13.93 to $84.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $99.04 info
Change: -$0.690 (-0.69%) info
Market Cap: $9.141B info
SYRE
Nov 03, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $99.04 info
Change: -$0.690 (-0.69%) info
Market Cap: $9.141B info
SYRE
Oct 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $80.51
Real-time Price: $99.04 info
Change: +$18.53 (+23%) info
Market Cap: $9.141B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $99.04 info
Change: +$18.93 (+24%) info
Market Cap: $9.141B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $99.04 info
Change: +$17.88 (+22%) info
Market Cap: $9.141B info